Aurelia study ovarian
WebNov 30, 2024 · The primary end point investigated was objective response rate (ORR), and the protocol is designed to rule out a 12% ORR, based on expected outcomes with available single-agent chemotherapy from the AURELIA study (NCT00976911) in patients with platinum-resistant ovarian cancer who were previously treated with 1 to 2 therapies. WebPatients received single-agent chemotherapy (paclitaxel, PLD, or topotecan) alone or in combination with bevacizumab until disease progression or unacceptable toxicity (the AURELIA study). In this study, a significant benefit was observed in PFS in patients receiving bevacizumab plus chemotherapy (6.7 months) than in those receiving ...
Aurelia study ovarian
Did you know?
WebJun 29, 2024 · Results from the phase III AURELIA study, led by Pujade-Lauraine, showed that PFS almost doubled, from 3.4 to 6.7 months, when bevacizumab was added to single-agent chemotherapy (hazard ratio 0.48 ... WebOct 30, 2012 · AURELIA trial, palliative chemotherapy with bevacizumab in resistant, recurrent ovarian cancer . Dr Gunnar Kristensen – Norwegian Radium Hospital, Oslo, Norway ... It is important to bear in mind that the AURELIA study is the first study to show a real prolongation of at least progression free survival with any kind of treatment in this ...
WebAvastin plus chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) significantly increased PFS over chemotherapy alone in the AURELIA study (HR=0.38 … WebSep 19, 2024 · Median OS after ICI was 18.3 months (95 percent CI, 11.8–22.7) for our heavily pretreated population of patients. This OS was promising compared to inferior …
WebOvarian cancer data are based on recurrent OC only; Avastin is also indicated in stage III or IV OC after primary surgery, for which exposure data are not yet available. ... † In the Avastin GOG-0218 study, patients with stage III or IV epithelial ovarian, fallopian tube, ... In prOC, Grade 3–4 adverse reactions in AURELIA occurring at a ... WebMar 11, 2024 · The glimmer of hope was the phase 3 AURELIA study [NCT00976911], where bevacizumab [Avastin] was added to chemotherapy, and there was a statistically significant prolongation of PFS.
WebDec 1, 2024 · The study is designed to rule out a 12% ORR, based on expected outcomes with available single agent chemotherapy from the AURELIA study in patients with platinum-resistant ovarian cancer and one to two prior lines of therapy.
WebDec 1, 2024 · The addition of bevacizumab should be considered based on the results of the AURELIA study (NCT00976911) [155], ... in a predominantly platinum-resistant recurrent ovarian cancer [192]. In this study, it was observed that treatment produced an immunostimulatory environment, characterised by enhancement of IFNγ and … alamo senior citizens centerWebDec 1, 2024 · The SORAYA study was designed to rule out an ORR of 12%, decided based on expected outcomes from Roche’s AURELIA study that evaluated single-agent chemotherapy in platinum-resistant ovarian ... alamo serverWebaurelia: 1. a female given name: from Latin Aurelianus, a family name. alamo senior livingWebJun 8, 2024 · Patients and methods. Data from AURELIA (n = 326), a randomized trial of chemotherapy with or without bevacizumab, were used to identify baseline QoL domains [EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 and OV28] that were significantly associated with overall survival in multivariable Cox … alamo signature seriesWebThe AURELIA study, which was published in 2014, showed that the response rate with combination therapy containing bevacizumab was significantly higher than the rate with previous monotherapy options, at 27.3%. Bevacizumab and weekly paclitaxel had the highest response rate of the regimens in AURELIA, at approximately 50%. alamo side cutterWebSep 15, 2009 · AURELIA: A Multi-center, Open-label, Randomised, Two-arm Phase III Trial of the Effect on Progression Free Survival of Bevacizumab Plus Chemotherapy Versus … alamo sevierville tnWebApr 11, 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be determined. Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal treatment options for recurrent platinum-resistant ovarian cancer.MethodsPubmed, … alamo sf airport